Financial reports
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K/A
2022 FY
Annual report (amended)
10 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
22 Mar 23
10-Q
2022 Q3
Quarterly report
1 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
Current reports
8-K
Other Events
27 Mar 24
8-K
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
27 Mar 24
8-K
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
21 Mar 24
8-K
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
13 Mar 24
8-K
Pyxis Oncology Announces $50 Million Private Placement
28 Feb 24
8-K
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
28 Nov 23
8-K
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
7 Nov 23
8-K/A
Index to Consolidated Financial Statements
27 Oct 23
8-K
Pyxis Oncology Successfully Completes Acquisition of Apexigen
23 Aug 23
8-K
Pyxis Oncology Reports Financial Results for Second-Quarter 2023
11 Aug 23
Registration and prospectus
424B2
Prospectus for primary offering
3 Apr 24
S-3
Shelf registration
27 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Aug 23
POS AM
Prospectus update (post-effective amendment)
23 Aug 23
S-8
Registration of securities for employees
23 Aug 23
425
Business combination disclosure
11 Aug 23
425
Business combination disclosure
11 Aug 23
425
Business combination disclosure
30 Jun 23
424B3
Prospectus supplement
30 Jun 23
Other
EFFECT
Notice of effectiveness
4 Apr 24
UPLOAD
Letter from SEC
6 Sep 23
CORRESP
Correspondence with SEC
28 Aug 23
EFFECT
Notice of effectiveness
25 Aug 23
UPLOAD
Letter from SEC
16 Aug 23
EFFECT
Notice of effectiveness
3 Jul 23
CORRESP
Correspondence with SEC
29 Jun 23
UPLOAD
Letter from SEC
15 Jun 23
EFFECT
Notice of effectiveness
15 Nov 22
CORRESP
Correspondence with SEC
10 Nov 22